Suven Life Sciences Ltd, the Hyderabad-based biopharmaceutical company is working on 10 new molecules for central nervous system (CNS) disorders or ailments, plans to raise funds for further trials on one of these, SUVN-502 that is intended for the symptomatic treatment of Alzheimer’s disease, schizophrenia and other disorders of memory and cognition such as attention deficiency and hyperactivity disorder and Parkinson’s disease. CNS disorders account for around 35% of the total disease burden in the world’s seven largest pharmaceutical markets with sales estimated at over $100 billion (Rs4.63 trillion) out of the total global pharmaceutical market sales of $780 billion. The molecule, first-in-class, has successfully completed phase-I studies in
Suven is targeting a commercial launch of the drug in late 2013 or early 2014 for this the company needs around $20 million to fund the phase-IIa studies. The company has initiated talks with some global pharmaceutical firms to out-license the molecule. However, it is not confident of attractive upfront or milestone payments when the drug candidate is out-licensed before the tier-IIa studies. For this it plans to raise the required funds for taking up phase-IIa studies by going in for equity dilution. The valuations and milestone payments will be highly attractive if the results in phase-IIa studies are promising. If SUVN-502 is out-licensed now, it may get an upfront payment of some $30 million and if it out-licenses it after successful phase-IIa studies, it may get $130 million or so as upfront payment, (and) some $300 million over the period of trials and royalties in double-digit percentages once the drug hits the market.
This achievement is indeed commendable for a company the size of Suven especially since it is quite rare for even the biggest of pharma companies to discover a new chemical entity and that too for a difficult to treat disease like Alzheimer’s. It has already secured patents in nine countries including
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1823.60 |
| Dr. Reddys Lab | 1351.00 |
| Cipla | 1490.00 |
| Lupin | 2187.05 |
| Zydus Lifesciences | 980.70 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
